Feed / REGN

Regeneron Pharmaceuticals, Inc.

REGN

Healthcare · 833.92 +0.8% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Regeneron Pharmaceuticals, Inc.'s move is being confirmed by its market group.

REGN accounts for 11.9% of the group's measured movement across 7.8 effective names. raw member direction is mixed; 6 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#5 of 12 by movement share
Group movement share11.9%Absolute path energy—not portfolio weight
Relative path-0.82%aligned
Effective breadth7.8 / 12broad
Relative alignment6/12downside path · 4 counter-moving
Capital-flow agreement41%not yet clean
SEQUENCE READ

BMY, NBIX, BMRN moved materially before REGN. REGN crossed its material path threshold at 14:00 ET, 200 minutes after the first measured mover. HALO followed.

What changed
  • Revenue increased 19.0% versus the comparable filing period.
  • Operating margin fell 1.7 percentage points.
EVIDENCE COVERAGE

8 of 15 members in Biopharmaceuticals and Care are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 10 of 15 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ABBV begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.

Watch this read

Who this business touches

The relationships behind REGN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

RAREUltragenyx Pharmaceutical Inc.partnerApr 29, 2026 ▾

“Aflibercept 8 mg is known as EYLEA HD in the United States and EYLEA 8 mg in other countries.”

ALNYAlnylam Pharmaceuticals, Inc.partnerApr 29, 2026 ▾

“Alnylam We and Alnylam Pharmaceuticals, Inc.”

Depended on by

KNSAKiniksa Pharmaceuticals International, plcsupplierApr 28, 2026 ▾

“Pursuant to the Regeneron Agreement, we have entered into a supply agreement with Regeneron to purchase both clinical and commercial product.”

Filing peers

BCRXOCULABBV

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 39 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

REGN is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.